Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380778 | 0.88 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4375353 | 0.88 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL4378211 | 0.87 | MAPK14 (0.77) | MAPK14 | |
| SCHEMBL4383504 | 0.87 | MAPK14 (0.77) | MAPK14 | |
| SCHEMBL4373903 | 0.87 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4382826 | 0.84 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4469554 | 0.84 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL4376977 | 0.83 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4383471 | 0.83 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL4473803 | 0.83 | MAPK14 (0.55) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605768-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVIMG AGENT | SUNTORY LIMITED (JP) | 2005-12-21 | — | — | EP | claimed |
| WO-2004085582-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT | SUNTORY LIMITED (JP) | 2004-10-07 | — | — | WO | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| CN-101531631-A | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-100486576-C | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2009-05-13 | — | — | CN | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1605768-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVIMG AGENT | SUNTORY LIMITED (JP) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004085582-A2 | LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT | SUNTORY LIMITED (JP) | 2004-10-07 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885POLB 1610/4885THRB 1532/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885POLB 1676/4885THRB 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.